[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352380-105":59,"doc-detail-352380-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","real-world-data-based-assessment-of-therapy-related-myeloid-neoplasms-after-polyadp-ribose-polymerase-inhibitor-treatment-in-ovarian-cancer","Real-world data-based assessment of therapy-related myeloid neoplasms after poly(ADP-ribose) polymerase inhibitor treatment in ovarian cancer","","Real-world outcomes for ovarian cancer increasingly rely on poly(ADP-ribose) polymerase inhibitor therapy, yet late complications such as therapy-related myeloid neoplasms remain incompletely predicted. A retrospective analysis assessed 181 patients treated with PARPi at two Japanese institutions, comparing clinical characteristics and routine hematologic parameters between patients with and without t-MNs. Six patients developed t-MNs (3.3%), all previously exposed to multiple platinum regimens, with diagnosis often occurring beyond 5 years after initial cancer diagnosis. No definitive clinical predictors emerged, while WBC, hemoglobin, and platelet measures showed no significant between-group differences, and the WBC decline trend was larger in the t-MN group. Findings support ongoing long-term hematologic monitoring and survivorship care to clarify risk factors.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/real-world-data-based-assessment-of-therapy-related-myeloid-neoplasms-after-polyadp-ribose-polymerase-inhibitor-treatment-in-ovarian-cancer/352380/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/real-world-data-based-assessment-of-therapy-related-myeloid-neoplasms-after-polyadp-ribose-polymerase-inhibitor-treatment-in-ovarian-cancer/352380.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-19","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the study’s main goal regarding PARP inhibitor therapy in ovarian cancer?","Question",{"text":113,"@type":114},"To determine whether clinical features and routine hematologic laboratory values differ between ovarian cancer patients treated with PARP inhibitors who do versus do not develop therapy-related myeloid neoplasms.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How many patients developed therapy-related myeloid neoplasms, and what treatment background did they share?",{"text":118,"@type":114},"Therapy-related myeloid neoplasms developed in 6 of 181 patients (3.3%). All had received multiple platinum-containing regimens, and most were diagnosed more than 5 years after initial cancer diagnosis.",{"name":120,"@type":111,"acceptedAnswer":121},"Did the study identify clear clinical predictors or specific blood count differences?",{"text":122,"@type":114},"No definitive clinical predictors were identified. Routine measures such as white blood cell counts, hemoglobin, and platelet counts did not differ significantly between groups, though a larger WBC reduction trend was observed in the t-MN group.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},352380,1790168866,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","TYPE Original Research PUBLISHED 29 January 2026 DOI 10.3389/fonc.2026.1728766  \nOPEN ACCESS  \nEDITED BY  \nAnanya Datta Mitra,  \nUC Davis Health, United States  \nREVIEWED BY  \nElspeth Payne,  \nUniversity College London, United Kingdom Alireza Ghezavati,  \nQuest Diagnostics, United States  \n*CORRESPONDENCE  \nAkira Yokoi  \n [ayokoi@med.nagoya-u.ac.jp](ayokoi@med.nagoya-u.ac.jp)  \nRECEIVED 20 October 2025  \nREVISED 20 December 2025  \nACCEPTED 08 January 2026  \nPUBLISHED 29 January 2026  \nCITATION  \nUekusa R, Yokoi A, Watanabe E, Inoue M, Mizuno K, Yoshida K, Yoshikawa N, Niimi K, Suzuki S and Kajiyama H (2026) Real-world data-based assessment of therapy-related myeloid neoplasms after poly(ADP-ribose) polymerase inhibitor treatment in ovarian cancer.  \nFront. Oncol. 16:1728766 .  \ndoi: 10.3389/fonc.2026.1728766  \nCOPYRIGHT  \n© 2026 Uekusa, Yokoi, Watanabe, Inoue, Mizuno, Yoshida, Yoshikawa, Niimi, Suzuki and Kajiyama. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nReal-world data-based assessment of therapyrelated myeloid neoplasms after poly(ADP-ribose) polymerase inhibitor treatment in ovarian cancer  \nRyosuke Uekusa 1,2, Akira Yokoi 1,3*, Eri Watanabe 2, Mikako Inoue 1, Katsuhiko Mizuno 2, Kosuke Yoshida 1,3, Nobuhisa Yoshikawa 1, Kaoru Niimi 1, Shiro Suzuki 2 and Hiroaki Kajiyama 1  \n1 Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 2 Department of Gynecologic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan, 3 Institute for Advanced Research, Nagoya University, Nagoya, Japan  \nBackground: Poly(ADP-ribose) polymerase inhibitors (PARPi) have signiﬁcantly improved outcomes in ovarian cancer. However, therapy-related myeloid neoplasms (t-MNs) have emerged as rare but serious late complications. Although an increased incidence of t-MNs has been reported following PARPi exposure, clinical predictors remain poorly understood.  \nMethods: This retrospective study analyzed 181 patients with ovarian cancer treated with PARPi at two Japanese institutions. Clinical characteristics and routine hematologic parameters were compared between patients with and without t-MNs. Hematological values were assessed at initial diagnosis, PARPi initiation, 4 weeks after initiation, and at nadir within 12 weeks. Relative changes from initial diagnosis and from PARPi initiation to nadir were also evaluated. Results: t-MNs developed in 6 (3 .3%) patients. All patients in the t-MN group had received multiple platinum-containing regimens, and in ﬁve of the six cases, t-MN was diagnosed more than 5 years after initial diagnosis. No deﬁnitive clinical predictors were identiﬁed, although the t-MN group tended to have higher body mass index. Median white blood cell (WBC), hemoglobin, and platelet counts, as well as their relative changes from initial diagnosis or PARPi initiation to nadir, did not differ signiﬁcantly between the groups. However, the t-MN group exhibited a larger reduction in WBC count from PARPi initiation to nadir, not statistically signiﬁcant.  \nFrontiers in Oncology 01 [frontiersin.org](frontiersin.org)  \nConclusions: This real-world study highlights the importance of survivorship care in the era of improved outcomes for ovarian cancer. Continued long-term hematologic monitoring, along with the collection of more cases, is essential to elucidate risk factors for t-MNs in patients receiving PARPi therapy.  \nKEYWORDS  \nmyelodysplastic syndrome, ovarian cancer, PARP inhibitors, real-world data, therapyrelated myeloid neoplasms  \n1 Introduction  \nOvarian cancer is among the most lethal gy","cbCaiaSuLR8HrQbM","https://ap.wps.com/l/cbCaiaSuLR8HrQbM","pdf",1195887,"English","# Introduction\n# Methods\n# Results\n# Conclusions","[{\"question\":\"What was the study’s main goal regarding PARP inhibitor therapy in ovarian cancer?\",\"answer\":\"To determine whether clinical features and routine hematologic laboratory values differ between ovarian cancer patients treated with PARP inhibitors who do versus do not develop therapy-related myeloid neoplasms.\"},{\"question\":\"How many patients developed therapy-related myeloid neoplasms, and what treatment background did they share?\",\"answer\":\"Therapy-related myeloid neoplasms developed in 6 of 181 patients (3.3%). All had received multiple platinum-containing regimens, and most were diagnosed more than 5 years after initial cancer diagnosis.\"},{\"question\":\"Did the study identify clear clinical predictors or specific blood count differences?\",\"answer\":\"No definitive clinical predictors were identified. Routine measures such as white blood cell counts, hemoglobin, and platelet counts did not differ significantly between groups, though a larger WBC reduction trend was observed in the t-MN group.\"}]","Real-world data-based assessment of therapy-related myeloid neoplasms after poly(ADP-ribose) polymerase inhibitor treatment in ovarian cancer | PDF",1790099283,23,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/61bf4ddff3da9b2e8e71477646aa61db.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/94d2e3ca16d43e4422562196bba73812.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ea008b20b57afe7039fae0d05aec478c.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ece0a21e089eac233aad7e4436c0b7dc.webp",980,1385]